Remsima SC (Infliximab)
infliximab 120 mg/mL injection, 1 mL syringe · INJECTION · PBS code 12597B
AUTHORITY_REQUIREDWhat it costs
AU$332.8 PBS-determined price per 2 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2021-07-01.
- • Repeats: 0.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Severe Crohn disease
Balance of supply
Patient must have received insufficient therapy with this drug under the Initial treatment with subcutaneous form to complete 14 to 16 weeks initial treatment (intravenous and subcutaneous inclusive); AND
The treatment must provide no more than the balance of doses up to 14 to 16 weeks therapy available under Initial treatment; AND
Must be treated by a gastroenterologist; or
Must be treated by a consultant physician [internal medicine specialising in gastroenterology]; or
Must be treated by a consultant physician [general medicine specialising in gastroenterology]; or
Must be treated by a paediatrician; or
Must be treated by a specialist paediatric gastroenterologist.
Sponsor: Celltrion Healthcare Australia Pty Ltd ABN 66 625 407 105
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.